
Regulatory tracker: BMS' Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Be sure to come back regularly for …